DOCSLIB.ORG

Medperform Low Formulary July 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medperform Low Formulary July 2017 MedPerform Low Formulary July 2017 Foreword FORMULARY This document represents the efforts of the MedImpact Healthcare Systems EXCLUDED THERAPEUTIC THERAPEUTIC DRUG CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide DRUGS physicians and pharmacists with a method to evaluate the safety, efficacy and cost- ALTERNATIVES effectiveness of commercially available drug products. A structured approach to the clindamycin/tretinoin, VELTIN ACNE AGENTS, TOPICAL drug selection process is essential in ensuring continuing patient access to rational ZIANA drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ER, ANALGESICS, prescribing decisions that reflect the most current clinical consensus associated KADIAN with drug therapy decisions. NUCYNTA, NUCYNTA NARCOTICS ER This is accomplished through the auspices of the MedImpact P & T and Formulary ANALGESICS, BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, ANALGESICS, LAZANDA, fentanyl citrate lozenge As you use this Formulary, you are encouraged to review the information and NARCOTICS provide your input and comments to the MedImpact P & T and Formulary ONSOLIS, Committees. SUBSYS immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T and Formulary Committees use the following criteria in the gabapentin evaluation of drug selection for the MedPerform Formulary: Drug safety profile ACTIVE-PAC immediate-release Drug efficacy KIT, gabapentin & Comparison of relevant therapeutic benefits to current formulary agents of SMARTRX lidocaine/menthol topical, ANTICONVULSANTS similar use, and to minimize therapeutic duplication where possible GABA-V KIT, Cost-effectiveness relative to comparable therapies or capsaicin/methyl SMART RX salicylate/menthol topical GABA KIT How to Use the Formulary The Formulary is a list of medications available to MedImpact members under their ANTICONVULSANTS pharmacy benefit. All drugs are listed by their generic names and most common immediate-release (RESTLESS LEG proprietary (branded) name. The Formulary may be accessed by using the index, HORIZANT gabapentin, SYNDROME/POST either by generic or proprietary name (in capital letters) and by therapeutic drug ropinirole, pramipexole category. In situations where an FDA approved generic equivalent is available, HERPETIC NEURALGIA) brand names are listed for reference purposes only, and do not denote coverage FORFIVO XL bupropion ER ANTIDEPRESSANTS for the brand, unless specifically noted. Any drug not found in this Formulary listing, or any Formulary updates published by MedImpact shall be considered a IRENKA duloxetine ANTIDEPRESSANTS Non-Formulary drug. desvenlafaxine succinate KHEDEZLA ER, desvenlafaxine ER ANTIDEPRESSANTS All drugs are listed in each category in alphabetical order by generic name. Where an FDA approved generic is available for the listed generic name, the generic name (Ranbaxy) is bolded. PEXEVA paroxetine ANTIDEPRESSANTS For certain agents within the Formulary, a recommended prescribing guideline may ZUPLENZ ondansetron ODT ANTIEMETIC AGENTS apply. These are denoted throughout the document using the following symbols: NYATA nystatin topical ANTI-INFECTIVE AGE Age Edit Coverage may depend on patient age CU Concurrent Use Edit Coverage or lack thereof may depend upon DAXBIA cephalexin ANTI-INFECTIVE concurrent use of another drug MD Physician Specialty Edit Coverage may depend on prescribing ZIPSOR, ANTI-INFLAMMATORY diclofenac physician’s ZORVOLEX NON-STEROIDAL specialty or board certification PA Prior Authorization Requires specific physician request process QL Quantity Limit Coverage may be limited to specific quantities ANTI-INFLAMMATORY NAPRELAN naproxen per prescription and/or time period NON-STEROIDAL ST Step Therapy Coverage may depend on previous use of another drug ANTI-INFLAMMATORY VIVLODEX meloxicam Please refer to the prescribing guideline appendix within this document for details NON-STEROIDAL regarding specific agents. ANTI-INFLAMMATORY TIVORBEX indomethacin Benefit Coverage and Limitations NON-STEROIDAL This printed Formulary does not provide information regarding the specific coverage and limitations an individual member may be subject to. Many members naproxen & have specific benefit inclusions, exclusions, copays, or a lack of coverage, which esomeprazole ANTI-INFLAMMATORY are not reflected in the Formulary. magnesium, VIMOVO NON-STEROIDAL lansoprazole, The Formulary applies only to outpatient drugs provided to members, and does not COMBINATION AGENTS apply to medications used in inpatient settings. If a member has any specific omeprazole, or questions regarding their coverage, they should contact their Plan Sponsor or pantoprazole MedImpact at (800) 788-2949. ANTI-INFLAMMATORY DUEXIS famotidine & ibuprofen NON-STEROIDAL Excluded Agents COMBINATION AGENTS As new drugs become available, they will be considered for coverage under the ANTI-INFLAMMATORY MedPerform Formulary. The plan administrator has the right to decide what drugs are covered and to what extent, as well as the right to modify coverage including celecoxib & NON-STEROIDAL the exclusion of any prescription drugs. Please note that prescribing guidelines CAPXIB capsaicin/menthol topical CYCLOOXYGENASE-2 such as Prior Authorization, Step Therapy, Quantity Limit, etc., may still apply to patch (COX-2) SELECTIVE Formulary Therapeutic Alternatives. INHIBITOR immediate-release ANTI-INFLAMMATORY RAYOS prednisone STEROIDAL 37010 MedPerform Low Formulary – July 2017 i MedPerform LOW Formulary FORMULARY FORMULARY EXCLUDED THERAPEUTIC DRUG EXCLUDED THERAPEUTIC DRUG THERAPEUTIC THERAPEUTIC DRUGS CLASS DRUGS CLASS ALTERNATIVES ALTERNATIVES LEVITRA, DRUGS TO TREAT STENDRA, VIAGRA ZONACORT, dexamethasone ANTI-INFLAMMATORY IMPOTENCY STAXYN LOCORT 1.5mg tab STEROIDAL EMERGENCY diphenoxylate/atropi epinephrine 0.3mg MOTOFEN ANTI-MOTILITY TREATMENT OF ne AUVI-Q or 0.15mg auto- ALLERGIC REACTIONS codeine/pseudoephe injector HYCOFENIX ANTITUSSIVES (TYPE 1) drine/guaifenesin sol GENOTROPIN, APTENSIO XR, dextroamphetamine/ ATTENTION DEFICIT- HUMATROPE, ADZENYS XR amphetamine, HYPERACTIVITY NUTROPIN, ODT methylphenidate (ADHD)/NARCOLEPSY NUTROPIN AQ, OMNITROPE, GROWTH HORMONES HUMIRA, ENBREL, NUTROPIN AQ NORDITROPIN COSENTYX, NUSPIN, STELARA, CIMZIA, SAIZEN, XELJANZ/XR, KEVZARA, ZOMACTON OTEZLA, *SIMPONI AUTOIMMUNE DISEASE SIMPONI 50mg, VIEKIRA PAK, HARVONI, 100mg (*for HEPATITIS C TALTZ DAKLINZA EPCLUSA diagnosis of ESTROGEL DIVIGEL HORMONAL DEFICIENCY ulcerative colitis only) NATESTO, TESTIM, ANDROGEL, alendronate 70mg, BONE RESORPTION HORMONAL DEFICIENCY BINOSTO VOGELXO, AXIRON ibandronate INHIBITORS FORTESTA aspirin (OTC), amlodipine and DURLAZA CARDIOLOGY PRESTALIA HYPERTENSION clopidogrel benazepril hcl YOSPRALA aspirin (OTC) CARDIOLOGY APIDRA, GONITRO nitroglycerin CARDIOLOGY APIDRA SOLOSTAR, KELOCOTE, HUMALOG INSULINS BEAU RX DERMATOLOGY NOVOLOG, RECEDO NOVOLOG DERMAPAK tretinoin topical DERMATOLOGY FLEXPLEN PLUS LEVEMIR, ACCUCAINE lidocaine topical DERMATOLOGY BASAGLAR, LANTUS, TOUJEO INSULINS PEDIPAK ciclopirox DERMATOLOGY TRESIBA OTC EMOLLIENTS NOVOLIN HUMULIN INSULINS (EUCERIN, atorvastatin, lovastatin, SYNERDERM CETAPHIL, DERMATOLOGY ALTOPREV, pravastatin, LIPID IRREGULARITY VASELINE, LESCOL XL AQUAPHOR) simvastatin, URE-K, rosuvastatin KERALAC, fenofibrate/ UTOPIC, ANTARA micronized/ LIPOTROPICS urea 40%, urea 50% DERMATOLOGY UREVAZ, nanocrystallized DERMASORB balsalazide LOWER XM DELZICOL, disodium, APRISO, GASTROINTESTINAL diclofenac sodium DERMATOLOGY - DIPENTUM LIALDA, PENTASA, PENNSAID DISORDERS 1% topical ANTIINFLAMMATORY sulfasalazine ADLYXIN, ONZETRA, BYDUREON, TRULICITY, ZEMBRACE DIABETES sumatriptan MIGRAINE BYETTA, VICTOZA SYMTOUCH, TANZEUM TREXIMET TRULICITY, REBIF, GILENYA, XULTOPHY, VICTOZA, LANTUS, DIABETES PLEGRIDY, SOLIQUA TECFIDERA, TOUJEO EXTAVIA MULTIPLE SCLEROSIS INVOKANA, AVONEX, INVOKAMET,INVOK GLATOPA, FARXIGA, AMET XR, AUBAGIO DIABETES Individual vitamin MULTIVITAMIN XIGDUO XR JARDIANCE, METHAVER SYNJARDY, components PREPARATIONS SYNJARDY XR Nasal triamcinolone, GLUMETZA metformin ER DIABETES OMNARIS, flunisolide, ZETONNA, fluticasone, NASAL ANTI- NESINA, JENTADUETO, BECONASE AQ, budesonide, INFLAMMATORY KAZANO, JENTADUETO XR, TICANASE mometasone, OSENI, TRADJENTA, DIABETES QNASL ONGLYZA, JANUVIA, NASAL ANTI- Azelastine & KOMBIGLYZE JANUMET, INFLAMMATORY/ANTI- TICALAST fluticasone nasal XR JANUMET XR HISTAMINE sprays ALL OTHER COMBINATION MANUFACTUR ABBOTT phentermine & ERS OF (PRECISION AND DIABETIC SUPPLIES QSYMIA OBESITY AGENTS DIABETIC TEST FREESTYLE (TEST STRIPS, METERS) topiramate STRIPS AND BRAND) METERS 37010 MedPerform Low Formulary – July 2017 ii MedPerform LOW Formulary FORMULARY EXCLUDED THERAPEUTIC DRUG THERAPEUTIC DRUGS CLASS ALTERNATIVES latanoprost, travoprost, OPHTHALMIC ZIOPTAN LUMIGAN, GLAUCOMA TRAVATAN Z NARCAN NASAL OPIOID REVERSAL EVZIO SPRAY LASTACAFT, BEPREVE, PATADAY, OPHTHALMIC EMADINE, olopatadine ANTIHISTAMINES PAZEO ORAL/PHARYNGEAL ARESTIN N/A DISORDERS lipase/protease/amyl PANCREAZE, ase, CREON, PANCREATIC ENZYMES PERTZYE ZENPEP AIRDUO RESPICLICK AND AUTHORIZED ADVAIR, BREO GENERIC ELIPTA, RESPIRATORY ASTHMA FLUTICASONE/ SYMBICORT, SALMETEROL DULERA (55/14mcg, 113/14mcg, and 232/14mcg) UTIBRON, STIOLTO
Load more

Recommended publications
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study
    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
    [Show full text]
  • 2021 National Formulary 3Rd Quarter Edition
    2021 National Formulary 3rd Quarter Edition Last Revised: 08/18/2021 Version 2021Q3c Table of Contents OVERVIEW 4 CARDIOVASCULAR (HEART) DRUGS 14 Alpha & Beta Blockers 14 COVERAGE LIMITATION 4 Antihypertensive Combinations 14 Calcium Channel Blockers (CCBs) 14 COMPOUNDED DRUGS 4 ACE Inhibitors without & with Diuretics 15 DRUG PLACEMENT DETERMINATION 4 ACE Inhibitors / CCB Combinations 15 ARBs without & with Diuretics 15 PREFERRED BRAND PRODUCTS 5 ARB Combinations 15 Naprilysin Inhibitors 15 GENERIC SUBSTITUTION 5 Diuretics 15 Renin Inhibtors 16 SINGLE & DUAL SOURCE GENERICS 5 Antiarrhythmics/Anti-Ischemic 16 Cardiac Glycosides 16 PRIOR AUTHORIZATIONS, STEP EDITS & QTY LIMITS 6 Vasodilators, Coronary, Nitrates/Vasodilators, Sympatholytics 16 EXCLUDED DRUGS 6 Other Drugs 16 NON-LISTED DRUGS & DRUG CATEGORIES 7 ANTIHYPERLIPIDEMIC (CHOLESTEROL) DRUGS 17 Statins & Statin/CCB Combinations 17 FORMULARY MODIFICATIONS & CHANGES 7 Bile Acid Sequestrants, Liver Drugs 17 Fibrates 17 BIOSIMILARS 7 ACL Inhibitors 17 Other Drugs 17 MAJOR CHANGES TO THE PDL 7 PANCREATIC DRUGS 18 ANTIBIOTICS 8 Penicillins & Cephalosporins 8 KIDNEY & URINARY / UROLOGICAL DRUGS 18 Tetracyclines 8 Benign Prostate Hyperplasia 18 Macrolides & Clindamycins 8 Urologic Drugs / Other Drugs 18 Sulfonamides, Sulfones & Ketolides 8 Erectile Dysfunction Drugs 18 Quinolones 8 Gout Drugs – Purine Inhibitors 19 Miscellaneous Antibiotics 8 Urinary Ph Modifiers 19 Potassium & Electrolytes 19 ANTI-VIRALS 9 Phosphorus/Calcium/Electrolyte Depleters 19 General Antivirals 9 HIV Antiviral Drugs 9 OSTEOPOROSIS (BONE) DRUGS 20 HIV Pre-Exposure Propylaxis Drugs 9 ANTI-INFLAMMATORY / ANALGESIC (PAIN) DRUGS 20 ANTI-INFECTIVES 10 Anti-Inflammatory Drugs (NSAIDS) 20 Anaerobic Anti-Infectives 10 COX-II Drugs 21 Antiparasitics 10 Analgesics, Narcotics (Opioids) 21 Antimalarials & Antiprotozoals 10 Analgesics, Salicylates, Non-Salicylates, Other 21 Antihelmintic Drugs 10 CENTRAL NERVOUS SYSTEM DRUGS 22 ANTIEMETICS 10 Anti-Anxiety Drugs (Benzodiazepines) 22 Sedative/Sleeping Drugs 22 NEUROLOGIC DRUGS 11 A.D.D.
    [Show full text]
  • Jos Journal 2
    POST-OPERATIVE AUDIT OF G6PD-DEFICIENT MALE CHILDREN WITH OBSTRUCTIVE ADENOTONSILLAR ENLARGEMENT AT UNIVERSITY COLLEGE HOSPITAL, IBADAN, NIGERIA. John EN1, Totyen EL1, Jacob N2, Nwaorgu OGB1 1 .Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria 2. Department of paediatrics, University College Hospital, Ibadan, Nigeria All correspondences and request for reprint to Dr John EN, Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria Email: [email protected] Telephone: +2348036240109 Abstract Background: G6PD deficiency ranks among the commonest hereditary enzyme deficiency worldwide and notable as a predisposing condition to haemolyticcrises. The fear of possible untoward effects is often expressed by parents of G6PD deficient male children scheduled for surgery after obtaining an informed and understood consent. The parental perception of obstructive adenotonsillar enlargement in this condition was also appraised. Methods: A retrospective chart review of all G6PD deficient male children between ages 1 to 7years who had adenotonsillectomy over a 3year period at University college Hospital, Ibadan, Nigeria. Results: The patients comprised of 22 G6PD deficient male children diagnosed shortly after birth upon development of neonatal jaundice. Fifteen(68.2%) and 6(27.3%) of the patients subsequently developed episodes of drug- induced haemolysis and non-haemolytic drug reactions prior to undergoing adenotonsillectomy by the otolaryngologists. None of the patients was observed to develop haemolytic crises up to 2weeks post-adenotonsillectomy. From the parental perception and responses in the follow-up period,all 22(100%) patient had resolution of noisy breathing, 20(91%) had improvement of snoring and apnoeic spells. Only 15 (68%) were reported to stop mouth-breathing.
    [Show full text]
  • Annex 4: Drug Dosages for Children (Formulary)
    Medicines Dosage Form Dose according to body weight (calculate if weight is below or over) 3-6 kg 6-10 kg 10-15 kg 15-20 kg 20-29 kg albendazole 200 mg (half tablet) 12-24 months chewable tablet, 400mg 400 mg (one tablet) over 24 months amodiaquine 10 mg base/kg/3 days (total dose 30 mg base/kg) tablet, 200mg - - 1 1 1 amoxicillin 15 mg/kg/dose for 7 days tablet/capsule 250 mg ¼ ½ ¾ 1 1½ oral suspension, 125mg/5ml 2.5 ml 5 ml 7.5 ml 10 ml - non-severe pneumonia: 25 mg/kg 2 times per day for 3 days tablet/capsule 250 mg ½ 1 1½ 2 2½ oral suspension, 125mg/5ml 5 ml 10 ml 15 ml - - ampicillin IM 50 mg/kg/6 hours Vial of 500 mg mixed with 2.1 ml 1 ml 2 ml 3 ml 5 ml 6 ml sterile water to give 500 mg/2.5 ml artemether IM 3.2 mg/kg once on day 1 injection, 40mg/ml in 1ml ampoule then injection, 80mg/ml in 1ml ampoule see Chapter 5, management of the child with malaria IM 1.6 mg/kg daily until oral therapy is possible, total therapy one week artemether + fixed dose treatment (20+120 mg) twice daily for 3 days tablet 10+120 mg see Chapter 5, management of the child with malaria lumefantrine artesunate severe malaria: IV or IM 2.4 mg/kg over 3 minutes at 0, 12 and 24 vial of 60 mg in 0.6 ml with 3.4 ml hours on day 1.
    [Show full text]
  • INTEGRIS Formulary July 2017
    INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T
    [Show full text]
  • Printed Formulary Catalog Basic
    Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees.
    [Show full text]
  • Estrogens, Estrogen Agonists/Antagonists, and Calcitonin Nelson B
    48 Estrogens, Estrogen Agonists/Antagonists, and Calcitonin Nelson B. Watts Estrogen 408 Calcitonin 409 Estrogen Agonists/Antagonists (Selective Estrogen Receptor Summary 410 Modulators or Serms) 409 Selected Readings 410 Thus, it appears that estrogen has protective effects on ESTROGEN the skeleton only for as long as it is taken. However, women who take estrogen and then stop should be no It is well established that osteoporosis is more common worse off compared with women who have never taken in women than men and fracture risk increases dramati- estrogen at all. cally after menopause. The relationship between estro- Following results of the WHI, estrogen treatment is gen defi ciency and osteoporosis was fi rst suggested in the recommended for relief of menopausal symptoms, but in mid-1900s when Albright showed that treatment with the lowest dose and for the shortest time necessary. Most estrogen reversed the negative calcium balance in post- women are not suffi ciently symptomatic at menopause menopausal women. The positive effects of estrogen on to require estrogen therapy, and most who require estro- peak bone mass and on bone loss have been demon- gen will be able to stop after a few years. However, a strated in both men and women. For years, estrogen was minority will require estrogen long-term. For those considered the treatment of choice for postmenopausal women, estrogen may be suffi cient for prevention and/or women and widely advocated for prevention of bone loss, treatment of osteoporosis. with numerous trials showing prevention of bone loss Several different forms of estrogen are available for in recently menopausal women and increased of bone therapeutic use (e.g., estradiol, conjugated estrogen ester- mineral density (BMD) in women with postmenopausal ifi ed estrogens, etc.) as well as several routes of adminis- osteoporosis.
    [Show full text]
  • New Zealand Data Sheet
    1 PARNATE tranylcypromine film-coated tablets 10 mg New Zealand Data Sheet 1 PARNATE® (10 MG FILM-COATED TABLETS) PARNATE 10 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Parnate 10 mg film-coated tablets: each tablet contains tranylcypromine sulfate equivalent to 10 mg of tranylcypromine. Excipients with known effect: each tablet contains sucrose 6 mg. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Parnate 10 mg film-coated tablets contain "geranium rose" coloured, biconvex, film-coated tablets. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. It is not recommended for use in mild depressive states resulting from temporary situational difficulties. 4.2 Dose and method of administration Adults Begin with 20 mg a day given as 10 mg in the morning and 10 mg in the afternoon. If there is no satisfactory response after two weeks, add one more tablet at midday. Continue this dosage for at least a week. A dosage of 3 tablets a day should only be exceeded with caution. When a satisfactory response is established, dosage may be reduced to a maintenance level. Some patients will be maintained on 20 mg per day, some will need only 10 mg daily. If no improvement occurs, continued administration is unlikely to be beneficial. 1 2 PARNATE tranylcypromine film-coated tablets 10 mg When given together with a tranquilliser, the dosage of Parnate is not affected. When the medicine is given concurrently with electroconvulsive therapy, the recommended dosage is 10 mg twice a day during the series and 10 mg a day afterwards as maintenance therapy.
    [Show full text]
  • Furazolidone Drug Information, Professional 7/8/18 19:50
    Furazolidone Drug Information, Professional 7/8/18 19:50 Furazolidone (Oral-Local) VA CLASSIFICATION Primary: AM600 Secondary: AP109 Commonly used brand name(s): Furoxone; Furoxone Liquid. Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s). †Not commercially available in Canada. Category: Antibacterial (oral-local)— antiprotozoal— Note: Furazolidone is a broad-spectrum anti-infective that is effective against most gastrointestinal tract pathogens. {01} Indications Accepted Cholera (treatment)—Furazolidone is indicated as a secondary agent in the treatment of cholera caused by Vibrio cholerae (V. comma) . {01} {02} {03} {04} {05} {07} {09} {15} {18} {19} Diarrhea, bacterial (treatment)—Furazolidone is indicated as a secondary agent in the treatment of bacterial diarrhea caused by susceptible organisms. Furazolidone is active in vitro against Campylobacter jejuni, Enterobacter aerogenes, Escherichia coli, Proteus species, Salmonella species, Shigella species, and staphylococci. However, clinical studies on the effectiveness of furazolidone in some types of bacterial diarrhea have been inconclusive or conflicting. {01} {02} {25} {26} https://www.drugs.com/mmx/furazolidone.html Página 1 de 12 Furazolidone Drug Information, Professional 7/8/18 19:50 Giardiasis (treatment)—Furazolidone is indicated as a secondary agent in the treatment of giardiasis caused by Giardia lamblia . {01} {02} {03} {04} {05} {06} {07} {08} {09} {13} {14} {16} —Not all species or strains of a particular organism may be susceptible to furazolidone. Pharmacology/Pharmacokinetics Physicochemical characteristics: Molecular weight— 225.16 {10} Mechanism of action/Effect: Microbicidal. Furazolidone interferes with several bacterial enzyme systems. It neither significantly alters normal bowel flora nor results in fungal overgrowth.
    [Show full text]
  • AHFS Therapeutic
    AHFS Therapeutic AHFS Therapeutic Class Description HICL HICL Description Program Edit Criteria 1 Edit Criteria 2 Edit Criteria 3 Edit Criteria 4 Edit Criteria 5 Class 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 0.667000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 0.750000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 1.500000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 2.000000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 2.500000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 3.000000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 3.750000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 6.000000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 7.500000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE Medical Exception Required 282032 RESPIRATORY AND CNS STIMULANTS 000007 CAFFEINE/DEXTROSE PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000008 CAFFEINE/MULTIVITAMIN PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000009 CAFFEINE/ETHYL ALCOHOL PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000010 CAFFEINE/SODIUM BENZOATE PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000011 CAFFEINE CITRATE
    [Show full text]
  • REVIEW Estrogens and Atherosclerosis
    R13 REVIEW Estrogens and atherosclerosis: insights from animal models and cell systems Jerzy-Roch Nofer1,2 1Center for Laboratory Medicine, University Hospital Mu¨nster, Albert Schweizer Campus 1, Geba¨ude A1, 48129 Mu¨nster, Germany 2Department of Medicine, Endocrinology, Metabolism and Geriatrics, University of Modena and Reggio Emilia, Modena, Italy (Correspondence should be addressed to J-R Nofer at Center for Laboratory Medicine, University Hospital Mu¨nster; Email: [email protected]) Abstract Estrogens not only play a pivotal role in sexual development but are also involved in several physiological processes in various tissues including vasculature. While several epidemiological studies documented an inverse relationship between plasma estrogen levels and the incidence of cardiovascular disease and related it to the inhibition of atherosclerosis, an interventional trial showed an increase in cardiovascular events among postmenopausal women on estrogen treatment. The development of atherosclerotic lesions involves complex interplay between various pro- or anti-atherogenic processes that can be effectively studied only in vivo in appropriate animal models. With the advent of genetic engineering, transgenic mouse models of atherosclerosis have supplemented classical dietary cholesterol- induced disease models such as the cholesterol-fed rabbit. In the last two decades, these models were widely applied along with in vitro cell systems to specifically investigate the influence of estrogens on the development of early and advanced atherosclerotic lesions. The present review summarizes the results of these studies and assesses their contribution toward better understanding of molecular mechanisms underlying anti- and/or pro-atherogenic effects of estrogens in humans. Journal of Molecular Endocrinology (2012) 48, R13–R29 Introduction circumstances, these hormones promote the develop- ment of atherosclerosis.
    [Show full text]